Abstract
Intravenous 177Lu-high-affinity (HA)-DOTATATE has shown promising results for the treatment of surgery- and radiotherapy-refractory meningiomas. We aimed to investigate the added value of intraarterial administration. Methods: Patients underwent at least 1 intravenous 177Lu-HA-DOTATATE treatment first and subsequent intraarterial cycles. Inpatient and intrapatient comparison was based on posttreatment 177Lu-HA-DOTATATE imaging 24 h after injection. The technical success rate and adverse events were recorded. Results: Four patients provided informed consent. The technical success rate was 100%, and no angiography-related or unexpected adverse events occurred. Intrapatient comparison showed an increased target lesion accumulation on both planar imaging (mean, 1220%) and SPECT/CT (mean, 1398%) after intraarterial administration, compared with intravenous administration. No unexpected adverse events occurred during follow-up. Conclusion: Intraarterial peptide receptor radionuclide therapy significantly increases tracer accumulation and is a safe and promising improvement for salvage meningioma patients. Future prospective studies on intraarterial peptide receptor radionuclide therapy are needed to determine the gain in efficacy and survival.
| Original language | English |
|---|---|
| Pages (from-to) | 406-409 |
| Number of pages | 4 |
| Journal | Journal of Nuclear Medicine |
| Volume | 63 |
| Issue number | 3 |
| Early online date | 22 Jul 2021 |
| DOIs | |
| Publication status | Published - 1 Mar 2022 |
Keywords
- PRRT
- intraarterial
- meningioma
- somatostatin receptor
Fingerprint
Dive into the research topics of 'Intra-arterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver